-+ 0.00%
-+ 0.00%
-+ 0.00%

Medpace Q3 2026 diluted EPS climbs 25% to $4.84

PUBT·10/21/2026 20:21:22
Listen to the news
Medpace Q3 2026 diluted EPS climbs 25% to $4.84
  • Medpace’s third-quarter 2026 GAAP diluted earnings rose 25% year over year to $4.84 per share.
  • Revenue increased 9% year over year to $716 million.
  • Net new business awards climbed 11% year over year to $873.4 million.
  • A new $1 billion stock repurchase authorization runs through December 31, 2028, replacing the previous authorization.
  • Full-year 2026 GAAP diluted earnings are forecast at $17.97 to $18.32 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021758492) on October 21, 2026, and is solely responsible for the information contained therein.